Instructions for Baralgin m (Metamizole sodium) 500 mg
English product name
Baralgin® M
Release form Baralgin m
tab 500 mg: 10, 20, 50 or 100 pcs
Description Baralgin m:
Tablets from white to almost white color, round, flat, with the engraving "BARALGIN-M" on one side, the risk - on the other and chamfer on two sides.
1 tab.
sodium metamisole 500 mg
Auxiliary substances: macrogol 4000 - 47 mg, magnesium stearate - 3 mg.
10 pcs - blister packs (5) - cardboard packs.
10 pcs - blister packs (10) - cardboard packs.
ATC codes
N02BB02 Metamizole sodium
Clinical-pharmacological groups / Group affiliation Baralgin m
Analgesic non-narcotic preparation
Active substance
sodium metamisole
Pharmacotherapy group Baralgin m
Analgesic nonarcotic agent
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at temperatures from 8 ° C to 25 ° C.
Testimony Baralgin m:
- severe acute or chronic pain syndrome in traumas and in the postoperative period,
- colic,
- oncological diseases and other conditions,
- in which other therapeutic methods of treatment are contraindicated;
- Fever resistant to other treatments.
Method of use, course and dosage Metamizole sodium:
A minimum dose sufficient to control pain and fever should be administered.
If you are experiencing or experiencing an increase in pain, you should consult your doctor to determine the cause of the symptoms.
Do not use the drug for a long time or increase the dose without a doctor's appointment. For long-term use, it is necessary to monitor the overall blood test (the number of blood elements).
A single dose for adults and adolescents over age five is 500 mg (1 tablet). The maximum single dose is 1000 mg (2 tablets). Unless otherwise prescribed, a single dose may be taken two to three times a day. The maximum daily dose is 2000 mg (four tablets).
Application for kidney disorders Metamizole sodium
Use the drug with caution in patients with pronounced kidney disorders (low doses are recommended due to the possibility of slowing the removal of sodium methamisole).
Use in liver disorders
Use with caution in patients with severe liver dysfunctions (low doses are recommended due to the possibility of slowing the elimination of sodium methamisole).
Terms of Sale
The drug is prescription.
Application in elderly patients
Elderly patients should reduce the dose, as the elimination of sodium methamisole metabolites can be slowed down.
Use in children Metamizole sodium
The use of the preparation is contraindicated for children and adolescents under the age of 15.
- Nosology Baralgin m (ICD codes)
- K80
- Gallstone disease [cholelitiasis] (incl. hepatic colic)
- N23
- Renal colic unspecified
- R10.4
- Other and unspecified abdominal pain (colic)
- R50
- Fever of uncertain origin
- R52.0
- Acute pain
- R52.2
- Other persistent pain (chronic)
- T14.9
- Injury unspecified
- Z98.8
- Other refined post-surgical conditions
Pharmacological effect Baralgin m:
The analgesic non-narcotic preparation of the pyrazolon group has analgesic, antipyretic and spasmolytic effects. Its mechanism of action has not been finalized. The available data suggest that methamizol and its major metabolite (4N-methylaminoantipyrin [4-MAA]) have a central and peripheral mechanism of action. In doses higher than therapeutic doses, anti-inflammatory effects may be achieved, possibly by suppressing prostaglandin synthesis.
